![Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study | SpringerLink Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-013-0063-y/MediaObjects/12325_2013_63_Fig2_HTML.gif)
Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study | SpringerLink
![PDF) Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study PDF) Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study](https://i1.rgstatic.net/publication/258203866_Dose_Conversion_Ratio_in_Hemodialysis_Patients_Switched_from_Darbepoetin_Alfa_to_PEG-Epoetin_Beta_AFFIRM_Study/links/546c9f570cf2c4819f22a03b/largepreview.png)
PDF) Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study
Epogen, Procrit (epoetin alfa) Retacrit (epoetin alfa-epbx) Aranesp ( darbepoetin alfa) Effective 06/05/2023 Plan ☒ MassHealth
![Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study | SpringerLink Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-013-0063-y/MediaObjects/12325_2013_63_Fig3_HTML.gif)